Global Bifidobacterium Longum Subsp. Infantis M-63 Market Growth 2024-2030

Global Bifidobacterium Longum Subsp. Infantis M-63 Market Growth 2024-2030

Bifidobacterium Longum Subsp. Infantis M-63 is a subspecies of Bifidobacterium longum infantis that mainly inhabits the intestines of human infants. Clinical studies have shown that it has a strong ability to utilize human milk oligosaccharides (HMO) contained in breast milk, which can improve the intestinal environment of healthy infants and young children. It is also known as the probiotic of the new era of HMO.

The global Bifidobacterium Longum Subsp. Infantis M-63 market size is projected to grow from US$ 43.7 million in 2024 to US$ 63.6 million in 2030; it is expected to grow at a CAGR of 6.4% from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “Bifidobacterium Longum Subsp. Infantis M-63 Industry Forecast” looks at past sales and reviews total world Bifidobacterium Longum Subsp. Infantis M-63 sales in 2023, providing a comprehensive analysis by region and market sector of projected Bifidobacterium Longum Subsp. Infantis M-63 sales for 2024 through 2030. With Bifidobacterium Longum Subsp. Infantis M-63 sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Bifidobacterium Longum Subsp. Infantis M-63 industry.

This Insight Report provides a comprehensive analysis of the global Bifidobacterium Longum Subsp. Infantis M-63 landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Bifidobacterium Longum Subsp. Infantis M-63 portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Bifidobacterium Longum Subsp. Infantis M-63 market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Bifidobacterium Longum Subsp. Infantis M-63 and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Bifidobacterium Longum Subsp. Infantis M-63.

United States market for Bifidobacterium Longum Subsp. Infantis M-63 is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Bifidobacterium Longum Subsp. Infantis M-63 is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Bifidobacterium Longum Subsp. Infantis M-63 is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Bifidobacterium Longum Subsp. Infantis M-63 players cover Mitushi Biopharma, Fengchen Group, Jiangsu Wecare Biotechnology Co., Ltd., Shenzhen Lefu Biotechnology Co., Ltd., Hebei Hongtao Bioengineering Co., Ltd., etc. In terms of revenue, the global two largest companies occupied for a share nearly

% in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Bifidobacterium Longum Subsp. Infantis M-63 market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
0-50 billion CFU/g
50-100 billion CFU/g
＞100 billion CFU/g

Segmentation by Application:
Food Additives
Medicines and Supplements
Feed Additives
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Mitushi Biopharma
Fengchen Group
Jiangsu Wecare Biotechnology Co., Ltd.
Shenzhen Lefu Biotechnology Co., Ltd.
Hebei Hongtao Bioengineering Co., Ltd.
Shandong Junle Biotechnology Co., Ltd.
Shandong Xinxiong Biotechnology Co., Ltd.
Newgen Biotech
Pharm-Rx
Rajvi Enterprise
Shandong Pingao Pharmaceutical Co., Ltd.
Shaanxi Chenming Biotechnology Co., Ltd.
Xi'an Minglang Biotechnology Co., Ltd.
Jiahe Biotechnology (Shanxi) Co., Ltd.
Shaanxi Ruimao Biotechnology Co., Ltd.
Shaanxi Baohe Biotechnology Co., Ltd.
Shaanxi Lesent Biotechnology Co., Ltd.
Shaanxi Shuoyang Biotechnology Co., Ltd.
Shaanxi Mufan Biotechnology Co., Ltd.
Xi'an An'Drong Biomedical Technology Co., Ltd.
Shaanxi Guanchen Biotechnology Co., Ltd.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Bifidobacterium Longum Subsp. Infantis M-63 market?

What factors are driving Bifidobacterium Longum Subsp. Infantis M-63 market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Bifidobacterium Longum Subsp. Infantis M-63 market opportunities vary by end market size?

How does Bifidobacterium Longum Subsp. Infantis M-63 break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.